BridgeMD
Randomized clinical trial to evaluate the efficacy of fibrin membrane graft with eye drops concentrated in autologous growth factors in primary pterygium surgery compared to amniotic membrane graft in terms of recurrence during the first year after surgery.
EU CTIS ID: 2025-520640-15-00
What this study is testing
To evaluate the efficacy, through the recurrence rate during the first postoperative year, of fibrin membrane graft and eye drops of autologous growth factor concentrate in primary pterygium surgery, comparing it with amniotic membrane graft.
- Phase III and phase IV (Integrated)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Primary pterygium, unilateral or bilateral, with fibrovascular proliferation growth.
- Patients aged between 20 and 60 years.
- Corneal invasion with risk of visual impairment and/or ocular discomfort due to pterygium.
You likely can't join if
- Previous pterygium surgery (recurrent pterygium).
- Pseudopterygium.
- Use of topical or systemic immunosuppressive or immunomodulatory treatment.
- Chronic use of topical ocular treatment except for artificial tears.
- History of eyelid or ocular surface disease.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.